Myeloid Sarcoma, FISH
Less than 1% of patients with acute myeloid leukemia (AML) will develop Myeloid Sarcoma (MS), characterized by the presence of one or more extramedullary collections of immature myeloid cells. MS can occur concurrently with AML, precede AML or occur during AML relapse. Common sites of involvement include bone, periosteum, soft tissues, and lymph nodes, and less commonly the orbit, intestine, mediastinum, epidural region, uterus, and ovary. Gingival or cutaneous infiltrates are most commonly seen in AML with a monocytic component. Rarely, MS may be seen in blast crisis of patients with Chronic Myelogenous Leukemia (CML) or progression of other myeloproliferative disorders or myelodysplastic disorders.
MS is classified as a unique presentation rather than a subgroup of AML by the World Health Organization. The most common genetic abnormalities seen in MS are the same as those seen in AML, namely fusion genes: RUNX1T1/ RUNX1 (t[8;21][q22;q22]), PML/RARA (t[15;17][q24;q21]), BCR/ABL1 (t[9;22] [q34;q11.2]), MYH11/CBFB (inv[16][q13.1q22]), and rearrangements of MLL (KMT2A; t[11q23;var]). These genetic alterations can be detected via Fluorescence in situ hybridization (FISH) utilizing one or more probes. For the diagnosis, prognosis and therapy selection cytogenetics including FISH remains the gold standard technique.
- As an aid in diagnosis of myeloid sarcoma
- Therapy selection and disease management
Abnormal findings present with abnormal limits for the RUNX1T1, RUNX1, ABL1, BCR, MYH11, CBFB, PML, RARA or MLL gene regions indicating myeloid lineage of the tumor. (This result usually indicates a t(15;17), which is associated with both de novo and therapy related APL. While this translocation reportedly has a favorable prognosis at diagnosis in APL, the prognostic significance in a myeloid sarcoma is unknown.)
In normal individuals, the result are within normal limits for the RUNX1T1, RUNX1, ABL1, BCR, MYH11, CBFB, PML, RARA and MLL gene regions.
Normal: The result is within normal limits for the RUNX1T1, RUNX1, ABL1, BCR, MYH11, CBFB, PML, RARA and MLL gene region
Formalin-fixed paraffin-embedded (FFPE) tumor tissue.
Stability
- Ambient: FFPE is stable in room temperature.
3-5 days.
- Oncol Res Treat. 2019;42(4):224-229. [PMID: 30840960]
- Leukemia. 2007 Feb;21(2):340-50. [PMID: 17170724]
- Ther Adv Hematol. 2011 Oct;2(5):309-16. [PMID: 23556098]
- Blood. 2000;96:4075-4083. [PMID: 11110676]
- Blood. 2010;116:354-365. [PMID: 20385793]